Catalent Inc (CTLT) Position Raised by Allianz Asset Management GmbH
Allianz Asset Management GmbH boosted its holdings in shares of Catalent Inc (NYSE:CTLT) by 64.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 696,631 shares of the company’s stock after purchasing an additional 273,861 shares during the period. Allianz Asset Management GmbH owned 0.52% of Catalent worth $27,810,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Invictus RG acquired a new stake in shares of Catalent in the 3rd quarter valued at $348,000. Pier Capital LLC acquired a new stake in shares of Catalent in the 3rd quarter valued at $5,545,000. OxFORD Asset Management LLP increased its stake in shares of Catalent by 7.2% in the 3rd quarter. OxFORD Asset Management LLP now owns 83,032 shares of the company’s stock valued at $3,280,000 after buying an additional 5,605 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Catalent by 3.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,378,508 shares of the company’s stock valued at $55,028,000 after buying an additional 43,355 shares during the period. Finally, Brown Advisory Inc. increased its stake in shares of Catalent by 7.1% in the 3rd quarter. Brown Advisory Inc. now owns 1,948,514 shares of the company’s stock valued at $77,784,000 after buying an additional 129,966 shares during the period. 99.49% of the stock is owned by hedge funds and other institutional investors.
CTLT has been the subject of a number of analyst reports. Bank of America reaffirmed a “buy” rating and set a $40.00 price objective (up from $38.00) on shares of Catalent in a research note on Tuesday, August 29th. BidaskClub raised Catalent from a “hold” rating to a “buy” rating in a research note on Friday, September 8th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a report on Thursday, September 7th. J P Morgan Chase & Co reiterated a “buy” rating and set a $40.00 target price on shares of Catalent in a report on Tuesday, August 29th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $45.00 target price on shares of Catalent in a report on Tuesday, August 29th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $44.25.
Catalent Inc (CTLT) traded up $0.38 during mid-day trading on Monday, reaching $39.72. The company’s stock had a trading volume of 579,100 shares, compared to its average volume of 909,727. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01. The company has a market capitalization of $5,277.18, a price-to-earnings ratio of 27.78, a PEG ratio of 2.55 and a beta of 1.41. Catalent Inc has a 52-week low of $24.30 and a 52-week high of $43.39.
Catalent (NYSE:CTLT) last posted its earnings results on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The firm had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.16 earnings per share. sell-side analysts expect that Catalent Inc will post 1.46 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/11/catalent-inc-ctlt-position-raised-by-allianz-asset-management-gmbh.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.